$60,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025."
You can find more data on corporate lobbying on Quiver Quantitative.
IONS Insider Trading Activity
IONS insiders have traded $IONS stock on the open market 91 times in the past 6 months. Of those trades, 0 have been purchases and 91 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 12 sales selling 203,468 shares for an estimated $14,161,179.
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 12 sales selling 216,005 shares for an estimated $13,811,605.
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 5 sales selling 206,683 shares for an estimated $12,434,411.
- JOSEPH H WENDER has made 0 purchases and 13 sales selling 128,800 shares for an estimated $8,660,121.
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) has made 0 purchases and 9 sales selling 71,401 shares for an estimated $5,841,599.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 8 sales selling 68,609 shares for an estimated $4,679,550.
- JOSEPH III KLEIN has made 0 purchases and 5 sales selling 68,000 shares for an estimated $4,320,000.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 6 sales selling 61,625 shares for an estimated $3,837,493.
- ELIZABETH L HOUGEN (EVP, Finance & CFO) sold 49,800 shares for an estimated $3,249,733
- JOAN E HERMAN has made 0 purchases and 2 sales selling 44,000 shares for an estimated $3,173,830.
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 54,909 shares for an estimated $3,098,620.
- BRIAN BIRCHLER (EVP, Corp and Development Ops) has made 0 purchases and 3 sales selling 31,900 shares for an estimated $2,333,366.
- JOSEPH LOSCALZO has made 0 purchases and 2 sales selling 32,000 shares for an estimated $2,164,040.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 29,207 shares for an estimated $1,604,121.
- B LYNNE PARSHALL has made 0 purchases and 5 sales selling 30,000 shares for an estimated $1,586,665.
- ALLENE M. DIAZ sold 1,427 shares for an estimated $60,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IONS Hedge Fund Activity
We have seen 250 institutional investors add shares of IONS stock to their portfolio, and 155 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,891,792 shares (-18.0%) from their portfolio in Q3 2025, for an estimated $189,181,032
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,485,000 shares (-65.4%) from their portfolio in Q3 2025, for an estimated $162,568,700
- DEERFIELD MANAGEMENT COMPANY, L.P. added 1,979,669 shares (+inf%) to their portfolio in Q3 2025, for an estimated $129,509,945
- BVF INC/IL removed 1,913,385 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $125,173,646
- MILLENNIUM MANAGEMENT LLC removed 1,869,957 shares (-70.6%) from their portfolio in Q3 2025, for an estimated $122,332,586
- BELLEVUE GROUP AG removed 1,608,747 shares (-20.5%) from their portfolio in Q3 2025, for an estimated $105,244,228
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,517,260 shares (+191.8%) to their portfolio in Q3 2025, for an estimated $99,259,149
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IONS Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Piper Sandler issued a "Overweight" rating on 11/04/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
- Barclays issued a "Overweight" rating on 10/30/2025
- Raymond James issued a "Strong Buy" rating on 10/30/2025
- Needham issued a "Buy" rating on 10/30/2025
- RBC Capital issued a "Outperform" rating on 10/30/2025
To track analyst ratings and price targets for IONS, check out Quiver Quantitative's $IONS forecast page.
IONS Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 21 analysts offer price targets for $IONS in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Yanan Zhu from Wells Fargo set a target price of $100.0 on 01/05/2026
- Luca Issi from RBC Capital set a target price of $95.0 on 12/17/2025
- Mani Foroohar from Leerink Partners set a target price of $100.0 on 12/15/2025
- Jason Gerberry from B of A Securities set a target price of $97.0 on 12/09/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $110.0 on 11/10/2025
- Allison Bratzel from Piper Sandler set a target price of $77.0 on 11/04/2025
- Gena Wang from Barclays set a target price of $95.0 on 10/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
